Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management

Hu, Jenny; Sadeghi, Parrish; Pinter‐Brown, Lauren; Yashar, Sharona; Chiu, Melvin

doi:10.1016/j.jaad.2006.09.005

Cited by 213 publications

(245 citation statements)

References 66 publications

Supporting

Mentioning

199

Contrasting

Unclassified

Order By: Relevance

“…Although NF-kB activation limits the clinical response to EGFR inhibitors, it is currently unclear whether the side effects commonly reported with these drugs would still occur by targeting NF-kB. Cutaneous side effects are often described in patients treated with EGFR inhibitors (monoclonal antibodies or small-molecule inhibitors) [71,72]. They include hair loss, acneiform eruption, paronychia, and xerosis.…”

Section: Reviewmentioning

confidence: 99%

EGFR and NF-κB: partners in cancer

Shostak

Chariot

2015

Trends in Molecular Medicine

191

160

View full text Add to dashboard Cite

Section: Reviewmentioning

confidence: 99%

EGFR and NF-κB: partners in cancer

Shostak

Chariot

2015

Trends in Molecular Medicine

191

160

View full text Add to dashboard Cite

“…In the 75% of patients treated with erlotinib developed skin reactions, most of which developed within 3 weeks of starting erlotinib [1,2]. The most frequent skin lesion is an acneiform eruption, but xerosis, paronychia, periungual granuloma, pruritus, hair changes, telangiectasia and hyperpigmentation are also known [3][4][5]. Additionally, uncommon mucocutaneous eruptions such as erosion, nodules, and purpura are also seen.…”

Section: Introductionmentioning

confidence: 99%

Erlotinib-induced Adverse Skin Reactions

Yamamoto¹

2013

TOALLJ

View full text Add to dashboard Cite

Abstract:Erlotinib is low molecular-weight quinazolin derivatives which selectively inhibit the epidermal growth factor receptor (EGF-R) tyrosine kinase activity of the intracellular domain, block autophosphorylation and the subsequent signaling cascades. EGF-R is expressed on basal keratinocytes, sebocytes, the outer root sheath of hairs, and endothelial cells in the skin, and plays important roles in the regulation of differentiation, proliferation, apoptosis, attachment and migration of keratinocytes, inflammation, and wound healing. Therefore, inhibition of EGF-R causes a number of cutaneous adverse reactions. Among them, severe skin lesions are very stressful, and impair quality of life of patients. Moreover, they even bring disadvantages such as drug withdrawal or interruption. Several review papers describe representative or common skin lesions which appear either during the first a few weeks or at later phases. Common skin manifestations include papular and pustular follicular eruptions (acneiform eruption), xerosis, paronychia, pruritus, and abnormalities of hairs; however, other than those eruptions, several unusual lesions are also induced. Early intervention of dermatologists and management of skin lesions are quite important, because discontinuance of the drug is unfavorable for patients with clinical benefits for cancers. In this brief review, various cutaneous manifestations seen in Japanese patients treated with erlotinib (Tarceva) are shown, and current management of representative severe conditions is also described.

show abstract

“…Acneiform eruptions, paronychia, and xerosis have been the most commonly described cutaneous adverse events with erlotinib and gefitinib as well as with cetuximab, a monoclonal antibody EGFR inhibitor [14]. Eruptions affecting the hands and feet have frequently been described with the multitargeted TKIs and have been com-monly referred to as hand-foot syndrome, indicating a similarity to the acral erythema or palmar-plantar erythrodysesthesia seen with other chemotherapeutic agents such as cytarabine, fluorouracil, capecitabine, or doxorubicin.…”

Section: Introductionmentioning

confidence: 99%

Localized Palmar–Plantar Epidermal Hyperplasia: A Previously Undefined Dermatologic Toxicity to Sorafenib

et al. 2007

View full text Add to dashboard Cite

The development of multitargeted tyrosine kinase inhibitors has provided significant advances in the treatment of renal cell carcinoma. This case describes initial therapy for managing renal cell cancer with the administration of sorafenib, a multitargeted tyrosine kinase inhibitor. We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy.Mild-to-moderate dermatologic toxicity from sorafenib has been well described in the literature. We also review the current knowledge and the proposed hypothesis for the development of cutaneous events related to tyrosine kinase inhibitors. This particular case represents a unique form of dermatologic toxicity to sorafenib that has not previously been described in the literature. The Oncologist

show abstract

Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management

Cited by 213 publications

References 66 publications

EGFR and NF-κB: partners in cancer

EGFR and NF-κB: partners in cancer

Erlotinib-induced Adverse Skin Reactions

Localized Palmar–Plantar Epidermal Hyperplasia: A Previously Undefined Dermatologic Toxicity to Sorafenib

Contact Info

Product

Resources

About